›
^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersTEST:Archer™ FusionPlex™ Core Solid Tumor Panel
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Integrated DNA TechnologiesType:
Laboratory Developed Test
Related tests:
Archer’s FusionPlex Core Solid Tumor panel enables simultaneous detection of fusions, splice variants, key SNV/Indels, and relative RNA expression from the same input to drive cost efficiency. The panel features expanded SNV/Indel coverage over key genes, including tumor suppressors. With Anchored Multiplex PCR (AMP™) chemistry at the core and an integrated bioinformatic platform, FusionPlex targeted NGS assays offer streamlined RNA-based analysis from sample to data.
Cancer:
Breast Cancer, Colorectal Cancer, Gastric Cancer, Melanoma, Non Small Cell Lung Cancer, Pancreatic Cancer, Thyroid Gland Carcinoma
Gene:
BRAF (B-raf proto-oncogene), BRD3 (Bromodomain Containing 3), BRD4 (Bromodomain Containing 4), CTNNB1 (Catenin (cadherin-associated protein), beta 1), CYSLTR2 (Cysteinyl Leukotriene Receptor 2), DNAJB1 (DnaJ Heat Shock Protein Family (Hsp40) Member B1)
See More ...
BRAF (B-raf proto-oncogene), BRD3 (Bromodomain Containing 3), BRD4 (Bromodomain Containing 4), CTNNB1 (Catenin (cadherin-associated protein), beta 1), CYSLTR2 (Cysteinyl Leukotriene Receptor 2), DNAJB1 (DnaJ Heat Shock Protein Family (Hsp40) Member B1), EGFR (Epidermal growth factor receptor), ER (Estrogen receptor), ERBB4 (erb-b2 receptor tyrosine kinase 4), FGFR1 (Fibroblast growth factor receptor 1), FGFR2 (Fibroblast growth factor receptor 2), FGFR3 (Fibroblast growth factor receptor 3), HER-2 (Human epidermal growth factor receptor 2), KIT (KIT proto-oncogene, receptor tyrosine kinase), LTK (Leukocyte Receptor Tyrosine Kinase), MAP2K1 (Mitogen-activated protein kinase kinase 1), MAP3K8 (Mitogen-Activated Protein Kinase Kinase Kinase 8), MET (MET proto-oncogene, receptor tyrosine kinase), MYB (MYB Proto-Oncogene, Transcription Factor), MYBL1 (MYB Proto-Oncogene Like 1), NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1), NTRK2 (Neurotrophic tyrosine kinase, receptor, type 2), NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3), NUTM1 (NUT Midline Carcinoma Family Member 1), PAX8 (Paired box 8), PDGFRA (Platelet Derived Growth Factor Receptor Alpha), PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha), POLD1 (DNA Polymerase Delta 1), POLE (DNA Polymerase Epsilon), PPARG (Peroxisome Proliferator Activated Receptor Gamma), PRKCA (Protein Kinase C Alpha), PRKCB (Protein Kinase C Beta), RAF1 (Raf-1 Proto-Oncogene Serine/Threonine Kinase), RET (Ret Proto-Oncogene), ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS), STK11 (Serine/threonine kinase 11), TP53 (Tumor protein P53)
Method:
Next-Generation Sequencing (NGS)